Stoke Therapeutics Q1 2023 net loss $0.53/sh; cash $254.2M; mid-2023 STK-001 data expected

Stoke Therapeutics, Inc.

2023-Q1 EPS reported -$0.53 revenue$5,152,000

Net loss per share $0.53, revenue $5.2M from collaboration (up from $3.0M YoY).
Cash, equivalents and securities $254.2M, expected to fund operations to end of 2025.
On track to report Phase 1/2a STK-001 data mid-2023: safety & seizure frequency for up to 16 patients on 45mg.
UK MHRA authorized CTA for STK-002 Phase 1/2 study in ADOA; start expected early 2024.
Company plans to initiate a Phase 3 program in 2024, pending additional Phase 1/2a data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Stoke Therapeutics, Inc. reported three months ended March 31, 2023 results: net income -$22.5 million, EPS -$0.53.

Period: three months ended March 31, 2023
Net income: -$22.5 million
EPS: -$0.53
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2023 was $22.5 million, or $0.53 per share, compared to $24.6 million, or $0.66 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.